162 related articles for article (PubMed ID: 3168142)
1. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
3. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
4. Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit.
Cusack BJ; Young SP; Loseke VL; Hurty MR; Beals L; Olson RD
Cancer Chemother Pharmacol; 1992; 30(2):145-8. PubMed ID: 1600594
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
6. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; Charles BG
Aust Vet J; 2004 Dec; 82(12):769-72. PubMed ID: 15648940
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
9. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.
Webster LK; Cosson EJ; Stokes KH; Millward MJ
Br J Cancer; 1996 Feb; 73(4):522-4. PubMed ID: 8595168
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
Behnia K; Boroujerdi M
J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
[TBL] [Abstract][Full Text] [Related]
14. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats.
Cusack BJ; Musser B; Gambliel H; Hadjokas NE; Olson RD
Cancer Chemother Pharmacol; 2003 Feb; 51(2):139-46. PubMed ID: 12647015
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin clearance in the obese.
Rodvold KA; Rushing DA; Tewksbury DA
J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine.
Johansen PB; Jensen SE; Rasmussen SN; Dalmark M
Cancer Chemother Pharmacol; 1984; 13(1):5-8. PubMed ID: 6329539
[TBL] [Abstract][Full Text] [Related]
17. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.
Mushlin PS; Cusack BJ; Boucek RJ; Andrejuk T; Li X; Olson RD
Br J Pharmacol; 1993 Nov; 110(3):975-82. PubMed ID: 8298821
[TBL] [Abstract][Full Text] [Related]
18. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin pharmacokinetics in the rabbit.
Maniez-Devos DM; Baurain R; Trouet A; Lesne M
J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012
[TBL] [Abstract][Full Text] [Related]
20. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
